Can I Take Resveratrol with Praluent (Alirocumab)?

How Alirocumab (Praluent) Is Metabolized, and Why It Matters

Alirocumab does not pass through the liver's cytochrome P450 system. As a fully human IgG1 monoclonal antibody, it is broken down by proteolytic catabolism, the same cellular machinery that degrades endogenous immunoglobulins. This is the single most important fact for evaluating any supplement combination with Praluent.

Because no CYP enzyme handles alirocumab's clearance, inhibitors or inducers of CYP1A2, CYP2C9, or CYP3A4 cannot alter its plasma exposure in any meaningful way. The FDA label for alirocumab states explicitly that formal drug, drug interaction studies were not required for CYP pathways precisely because the metabolism route bypasses them entirely. [1]

What PCSK9 Inhibitors Actually Do

Alirocumab binds and neutralizes PCSK9, a serine protease that degrades LDL receptors on hepatocyte surfaces. By blocking PCSK9, alirocumab preserves receptor recycling, which increases LDL clearance from circulation. The ODYSSEY LONG TERM trial (N=2,341) demonstrated 61% mean LDL-C reduction from baseline with alirocumab 150 mg every 2 weeks at 24 weeks, compared with placebo (P<0.001). [2]

Elimination Pathway in Plain Terms

After subcutaneous injection, alirocumab is absorbed over roughly 3 to 7 days, reaches peak plasma concentration at 3 to 7 days, and has a half-life of 17 to 20 days. Clearance occurs via two parallel routes: a saturable, target-mediated route (binding to circulating PCSK9) and a non-saturable, non-specific proteolytic route. Neither route involves hepatic CYP enzymes, renal tubular secretion, or P-glycoprotein transport. [1]

This matters because the most common mechanism by which supplements interfere with drugs is enzyme inhibition or induction at CYP3A4, CYP2C19, or P-glycoprotein. Alirocumab sidesteps all three.

What Resveratrol Does in the Body

Resveratrol is a polyphenol stilbene found in red grape skin, Japanese knotweed (Polygonum cuspidatum), and peanuts. Most commercial supplements provide trans-resveratrol, the biologically active isomer, at doses ranging from 150 mg to 1,000 mg per day.

Bioavailability and Metabolism

Oral bioavailability of resveratrol is low, estimated at roughly 1% for unchanged trans-resveratrol due to rapid phase II metabolism (glucuronidation and sulfation in the gut wall and liver). A 2010 pharmacokinetic study published in Cancer Prevention Research (N=40) found peak plasma concentrations of free resveratrol below 10 ng/mL even at a 1,000 mg dose, with most circulating as sulfate and glucuronide conjugates. [3]

This poor bioavailability is relevant: the in vitro CYP3A4 inhibitory concentrations reported in cell studies are far higher than what resveratrol achieves in human plasma at typical supplement doses.

CYP Enzyme Effects

Resveratrol inhibits CYP3A4, CYP2C9, and CYP1A1 in vitro. A study in Drug Metabolism and Disposition showed IC50 values for CYP3A4 inhibition in the range of 10 to 30 micromolar. [4] Achieving those concentrations in human plasma at standard supplement doses (150 to 500 mg/day) is unlikely given the low bioavailability noted above.

For drugs that ARE CYP3A4 substrates (certain statins, calcium channel blockers, immunosuppressants), this interaction potential is real and should be evaluated carefully. For alirocumab, it is not applicable.

Hormonal and Cardiovascular Effects

Resveratrol has weak estrogenic activity, binding estrogen receptor alpha and beta with roughly 7,000-fold lower affinity than 17-beta-estradiol. [5] This matters for patients with hormone-sensitive conditions but is not a direct interaction with alirocumab's mechanism. Resveratrol also modestly inhibits platelet aggregation and may reduce thromboxane B2 production. Patients taking anticoagulants or antiplatelets alongside Praluent should flag resveratrol use to their care team.

The Direct Interaction Verdict: Pharmacokinetic vs. Pharmacodynamic

Evaluating any two agents requires separating two types of interaction.

Pharmacokinetic Interaction

A pharmacokinetic interaction changes how the body absorbs, distributes, metabolizes, or excretes a drug. For alirocumab, no pharmacokinetic interaction with resveratrol is plausible. The elimination pathways are entirely orthogonal. Resveratrol does not affect immunoglobulin catabolism, PCSK9 protein concentrations at therapeutic alirocumab doses, or subcutaneous absorption. No published case report, randomized controlled trial, or pharmacovigilance signal documents a pharmacokinetic interaction between any PCSK9 inhibitor monoclonal antibody and resveratrol as of the article's review date.

Pharmacodynamic Interaction

Pharmacodynamic interactions occur when two agents act on the same or related biological targets, producing additive, synergistic, or antagonistic effects.

Resveratrol has reported LDL-lowering activity in its own right. A meta-analysis of 21 randomized trials (N=1,202) published in Nutrients (2022) found that resveratrol supplementation reduced LDL-C by a mean of 4.5 mg/dL (95% CI: 0.9 to 8.1 mg/dL) compared with placebo. [6] That magnitude is modest relative to alirocumab's 60%+ LDL reductions, and additive benefit is theoretically possible rather than problematic.

The more clinically meaningful pharmacodynamic consideration is resveratrol's mild estrogenic activity in patients with hormone-sensitive cardiovascular profiles, and its platelet inhibition in patients already on dual antiplatelet therapy. Neither of these involves alirocumab directly, but both are worth disclosing.

HealthRX Interaction Classification for This Pair

The HealthRX medical team uses a three-tier framework for supplement, biologic interactions:

• Tier 1 (Avoid): Supplement directly impairs biologic absorption, distribution, or target binding with clinical evidence.
• Tier 2 (Monitor): No direct pharmacokinetic conflict, but overlapping pharmacodynamic effects require periodic lab review.
• Tier 3 (Disclose and Track): No known interaction; supplement disclosure recommended for completeness of clinical record.

Resveratrol with alirocumab falls into Tier 3. Patients do not need to stop either agent, but the combination should appear in the medication reconciliation record. If resveratrol doses exceed 1,000 mg/day or the patient is also taking a statin alongside Praluent (a common combination), the treating clinician should review the full list for CYP-mediated interactions between resveratrol and the statin.

What Happens If You Are Already Taking Both

Patients who started resveratrol before their Praluent prescription (or added a supplement after starting Praluent) do not need to discontinue either agent on the basis of a pharmacokinetic interaction concern. Here is what to do instead.

Disclose at Your Next Appointment

Bring the resveratrol product label to your next cardiology or primary care visit. Your provider needs the dose (mg per capsule, number of capsules per day) and the source (grape extract, knotweed, combined formula). Knotweed-derived resveratrol may contain trace stilbene analogs that have not been individually studied.

Request a Lipid Panel at 4 to 8 Weeks

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol recommends a fasting lipid panel 4 to 12 weeks after initiating or adjusting any LDL-lowering therapy to confirm response. [7] If you added resveratrol after your last alirocumab efficacy check, a repeat lipid panel at 4 to 8 weeks provides a clean baseline for the combined regimen.

Watch for These Symptoms

Resveratrol at doses above 1,000 mg/day has been associated with gastrointestinal symptoms (nausea, diarrhea) in roughly 10% of subjects in clinical trials. [3] It may also cause mild transaminase elevations at very high doses. Alirocumab itself does not commonly cause hepatotoxicity, but liver enzyme monitoring is reasonable if resveratrol dose is high. Report any new muscle aches, since patients on Praluent often co-administer a statin, and resveratrol's CYP2C9 inhibition could theoretically alter statin exposure.

Do Not Use Resveratrol as a Reason to Delay Praluent

Resveratrol's 4.5 mg/dL mean LDL reduction does not approach the reductions needed for secondary prevention in established ASCVD or familial hypercholesterolemia. The FOURIER trial (N=27,564), evaluating evolocumab (a related PCSK9 inhibitor), showed that lowering LDL-C to a median of 30 mg/dL reduced major cardiovascular events by 15% relative to placebo (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). [8] A supplement cannot substitute for that magnitude of reduction.

Resveratrol's Evidence Base for Cardiovascular Health

Patients often ask whether resveratrol genuinely benefits cardiovascular health or whether it is worth taking alongside a potent LDL-lowering biologic. The evidence is more mixed than supplement marketing suggests.

Epidemiological Signal vs. Trial Results

The initial enthusiasm for resveratrol came from the "French paradox" observation and from in vitro and animal studies showing activation of SIRT1 (a NAD-dependent deacetylase implicated in longevity pathways). Human trial results have been less consistent.

A double-blind, randomized, crossover trial published in JAMA Internal Medicine (N=119 postmenopausal women, 2014) found that 75 mg/day resveratrol for 12 weeks did not significantly improve flow-mediated dilation or other cardiovascular biomarkers compared with placebo. [9]

Where the Evidence Is Stronger

Resveratrol's anti-inflammatory and antioxidant effects show more consistent signals in short-term trials. A 2018 meta-analysis in the American Journal of Clinical Nutrition (16 RCTs, N=675) found that resveratrol supplementation reduced C-reactive protein by 0.27 mg/L (P = 0.02) and tumor necrosis factor-alpha by 0.48 pg/mL (P = 0.03) versus placebo. [10] Whether that CRP reduction translates to cardiovascular event reduction in patients already on PCSK9 inhibitor therapy has not been studied in any dedicated trial.

The SIRT1 / Longevity Angle

Many patients taking resveratrol are motivated by longevity rather than cholesterol. SIRT1 activation by resveratrol has been demonstrated in cell and animal models. The clinical translation in humans remains under investigation, and no large randomized trial has reported mortality benefit from resveratrol supplementation in humans. Patients taking Praluent for ASCVD risk reduction are already benefiting from an evidence-based intervention; adding resveratrol for longevity purposes is a personal decision that current evidence neither strongly supports nor contradicts.

Resveratrol and Statins: The More Important Interaction to Check

Many patients taking alirocumab are also on a high-intensity statin such as atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg, as recommended by the 2022 ACC Expert Consensus Decision Pathway for PCSK9 inhibitor use. [11] The resveratrol, statin interaction, not the resveratrol, alirocumab interaction, is where clinical attention belongs.

Atorvastatin and CYP3A4

Atorvastatin is a CYP3A4 substrate. If resveratrol achieves meaningful CYP3A4 inhibition at high doses, it could increase atorvastatin plasma concentrations, theoretically raising myopathy risk. The clinical magnitude of this effect at standard supplement doses (150 to 500 mg/day) is uncharacterized in controlled human trials. Caution is warranted at resveratrol doses above 500 mg/day in patients on atorvastatin.

Rosuvastatin and CYP2C9

Rosuvastatin is partially metabolized by CYP2C9. Resveratrol inhibits CYP2C9 in vitro. The same bioavailability limitations apply: clinically significant inhibition at standard doses is unlikely but not ruled out. A prescriber reviewing the combination should consider a repeat creatine kinase check if the patient reports myalgia after starting resveratrol.

Simvastatin: Higher Concern

Simvastatin, though less commonly co-prescribed with PCSK9 inhibitors now, is highly dependent on CYP3A4. If a patient is on simvastatin plus alirocumab and adds resveratrol at doses above 500 mg/day, statin exposure elevation is a credible concern warranting prescriber review.

Special Populations

Patients with Familial Hypercholesterolemia

Alirocumab is FDA-approved for heterozygous familial hypercholesterolemia (HeFH). The ODYSSEY FH I and FH II trials (N=735 combined) showed alirocumab 75 to 150 mg every 2 weeks reduced LDL-C by 48.8 to 50.9% versus placebo at 24 weeks. [12] Patients with HeFH often pursue every available LDL-reduction strategy. Resveratrol's modest 4.5 mg/dL LDL reduction adds little in this context, but does not interfere with alirocumab's mechanism.

Postmenopausal Women

Resveratrol's weak estrogenic activity is a consideration in postmenopausal women, particularly those with a history of hormone receptor-positive breast cancer. The USPSTF and American Cancer Society do not recommend phytoestrogen supplementation as cardiovascular prevention in this group. A postmenopausal woman on Praluent for ASCVD risk should discuss resveratrol's estrogenic profile with both her cardiologist and her gynecologist before continuing.

Patients on Anticoagulation

Resveratrol inhibits platelet aggregation and may mildly prolong bleeding time. Patients on warfarin, apixaban, rivaroxaban, or clopidogrel alongside Praluent should flag resveratrol use. No case series has documented a clinically significant bleeding event attributable to this combination, but pharmacovigilance data are limited.

Practical Dosing and Timing Summary

No evidence supports a specific timing window between resveratrol and alirocumab. Alirocumab is injected subcutaneously once every 2 weeks and is not taken orally, so there is no shared gastrointestinal absorption step to worry about. Oral resveratrol can be taken at any time relative to the injection day.

If the patient is also taking an oral statin, the statin is unaffected by injection timing but may be affected by resveratrol at high doses (see statin section above). Taking resveratrol with food modestly improves its absorption; taking it with a high-fat meal can double peak plasma concentrations in some studies, which could increase the CYP inhibitory potential slightly. Patients on high-dose resveratrol who also take atorvastatin or rosuvastatin might reasonably separate the supplement from the statin dose by 4 to 6 hours, though this strategy is not evidence-based and is offered only as a conservative precaution.

Key Questions to Ask Your Prescriber

Bring these specific questions to your next appointment:

1. "I take [dose] mg of resveratrol daily. Can you add that to my medication list?"
2. "Should we check a lipid panel 4 to 8 weeks after I started adding the resveratrol?"
3. "I am also on [statin name and dose]. Is there any concern about resveratrol interacting with that?"
4. "My resveratrol label says it contains knotweed extract. Is that relevant?"
5. "Do you want me to keep taking resveratrol, pause it, or switch to a grape seed extract with lower stilbene content?"

The American College of Cardiology advises that clinicians routinely screen for supplement use in patients on lipid-lowering therapy because undisclosed supplements can complicate interpretation of lipid panel results. [11]